casino games free

casino games free

Badminton Star PV Sindhu's Wedding Preparations Begin In Udaipur

Smash That Replay Button: A 2024 Rewind of YouTube on TVSales in the semiconductor industry are surging thanks to the secular trends of artificial intelligence (AI) and electric vehicles (EVs). The semiconductor market is forecast to reach more than $600 billion in 2024, and rise to $1 trillion by 2030, making investments in chip companies a good way to capitalize on this growth. Two semiconductor industry leaders to consider are Wolfspeed ( WOLF 0.57% ) and Nvidia ( NVDA 3.08% ) . The former commands over 50% market share in the silicon carbide (SiC) wafer sector, while the latter captured headlines as its stock soared over 170% in 2024, through the week ending Dec. 13, thanks to its leadership in AI semiconductors. Both offer innovative technologies that make them attractive investments. Let's examine Wolfspeed and Nvidia to help you assess which is the better semiconductor stock for the long haul. A look at Wolfspeed What makes Wolfspeed a compelling investment is its focus on silicon carbide (SiC). The company developed the first commercial SiC wafers in 1991. They offer many advantages over the silicon widely used in the semiconductor industry today, particularly for EVs. Silicon carbide enables EVs to travel longer distances and reduce charging time. Wolfspeed believes its SiC sales will eventually grow to $3 billion in annual revenue as the EV market expands. For comparison, in the company's 2024 fiscal year, ended June 30, sales were $807.2 million. SiC's potential sounds promising, but the company has several hurdles to overcome first. It is trying to ramp up production at its SiC manufacturing plants, but the costs are high. For example, it generated sales of $194.7 million in its fiscal first quarter, ended Sept. 29, but the cost of revenue was $230.9 million. As a result, gross profit of $77.4 million at the end of fiscal 2024 turned into a loss of $36.2 million in the first quarter. It's also facing a cyclical downturn , causing softness in sales. Its $194.7 million in first-quarter revenue was down from $197.4 million in the previous year. The drop in sales, lack of profitability, and high production costs contributed to the resignation of Wolfspeed's CEO in November. Nvidia's AI strengths With the rise of AI, Nvidia has turned into a semiconductor powerhouse. It is now the world's leading semiconductor company by market cap. CEO Jensen Huang anticipated the need for accelerated computing in 1999 and introduced the graphics processing unit (GPU). Accelerated computing uses a dedicated processor to tackle intense tasks, such as the data crunching done by AI systems, rather than rely on a single CPU to do it all. This pioneering work in GPUs set the company up to enjoy massive sales to the cloud computing industry, where AI systems are housed. In its fiscal third quarter, ended Oct. 27, Nvidia's revenue reached a record $35.1 billion, an impressive 94% increase year over year. This led to a quarterly gross profit of $26.2 billion, nearly double the prior year's $13.4 billion. Nvidia's AI products are just getting started. The company is rolling out its latest computing architecture, called Blackwell. The new platform "pushes the boundaries of scientific computing," according to management. It will be a key revenue driver. Huang said current systems were trained on the human-generated data that existed before AI. Now, AI is starting to learn from its own synthetically produced content. This requires more computing power, which Blackwell delivers. "And so, we're seeing a lot of demand coming from a lot of different places," Huang said, indicating customers continue to crave his company's products for AI. Choosing between Wolfspeed and Nvidia Between Wolfspeed and Nvidia, the latter's strong sales, robust profits, and the ongoing demand seem to make it the clear choice between these two semiconductor giants. However, stock valuation is another important consideration. Comparing Wolfspeed and Nvidia using the price-to-sales ratio (P/S), a metric measuring how much investors are willing to pay for every dollar of sales, is revealing. Data by YCharts . Wolfspeed's recent struggles have resulted in its stock dropping over 80% this year through Dec. 13. Consequently, its P/S is the lowest it's been in years, while Nvidia's has done the opposite thanks to its AI success. Hence, Wolfspeed stock emerges as the better value, and could potentially deliver more upside over the long run, if the company can rebound from its current challenges. But because it faces a number of near-term headwinds, only investors with a high risk tolerance should consider purchasing shares. For others, Nvidia's success to date and the opportunities for continued sales growth with Blackwell make it the better long-term investment in the semiconductor sector.None

The Meme Glorification of Luigi MangioneMONROE, La. (AP) — Robert Davis Jr.'s 32 points led Old Dominion over UL Monroe 80-75 in overtime on Saturday. Davis shot 8 of 17 from the field, including 7 for 14 from 3-point range, and went 9 for 12 from the line for the Monarchs (4-8, 1-0 Sun Belt Conference). Sean Durugordon scored 15 points while shooting 4 of 11 from the field and 6 for 6 from the line and added five rebounds. R.J. Blakney had 11 points and went 5 of 11 from the field (0 for 4 from 3-point range). Old Dominion led 68-63 with 21 seconds left in regulation but the Warhawks came up with a Jacob Wilson 3-pointer, a Jalen Bolden steal and two free throws by Bolden to force overtime. In OT, Davis hit a tying 3-pointer with 1:09 to go and the Monarchs held the Warhawks scoreless over the final 97 seconds. The Warhawks (4-10, 0-1) were led by Wilson, who recorded 23 points, six rebounds and three steals. Bolden added 17 points and two steals for UL Monroe. Tyreese Watson finished with 14 points and six assists. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Agricultural Biotechnology Market Forecast: Size, Share, Growth, Key Drivers and Regional Trends for 2024 to 2031 | 12-21-2024 06:59 PM CET | Health & Medicine Press release from: Coherent Market Insights Agricultural Biotechnology Market This report on the Agricultural Biotechnology market offers an comprehensive analysis of the current trends, market size, and projections up to 2031. Combining qualitative and quantitative insights, the report covers key trends, challenges, opportunities, market size, growth forecasts, and recent developments. It also evaluates government policies, market dynamics, cost structures, and the competitive landscape, while highlighting emerging advancements and future growth potential. The report further highlights year-over-year growth rates and calculates the Compound Annual Growth Rate (CAGR), offering insight into market performance and future projections. Several analytical frameworks, such as Porter's Five Forces, PESTLE, and Value Chain Analysis offer a holistic view of the market, enabling businesses to navigate both current challenges and future opportunities. Ultimately, This research offers valuable guidance for both industry leaders and newcomers navigating market shifts and upcoming trends. 👉 Purchase This Premium Report Upto 45% Discount at: https://www.coherentmarketinsights.com/promo/buynow/2027 🎯 Scope of Agricultural Biotechnology Market Report: This report provides a detailed analysis of the Agricultural Biotechnology market, covering historical data, current trends, and future projections. It explores key market drivers, challenges, and technological advancements that will shape the market's growth. The competitive landscape is analyzed, highlighting major players, innovators, and emerging startups. Regional insights are provided to offer a breakdown of market performance across key geographic areas. Through a combination of primary and secondary research, the report presents a balanced view of the market, considering both opportunities and challenges. Key factors such as government policies, economic influences, and R&D advancements are also examined to give a clear picture of the market's future potential. 🔑 Highlights and Key Insights of the Report: • Overview of Key Insights and Findings • Market Size and Future Growth Forecasts • Key Trends Shaping the Agricultural Biotechnology Market • Analysis of Key Market Competitors • Understanding Customer Segments and Behavior • Factors Driving and Restricting Market Growth • SWOT Analysis: Strengths, Weaknesses, Opportunities, and Threats • Identifying Growth Opportunities in the Agricultural Biotechnology Market • Strategic Insights for Market Growth 🔍 Detailed Research Methods and Market Insights of Agricultural Biotechnology Market Report : The research employs a systematic approach and various techniques to collect, analyze, and interpret data, addressing specific research questions. It includes detailed figures, tables, and charts to support analysis, while examining industry value chains, trade patterns, and relevant regulations. This report offers a comprehensive analysis of competitors and market share information, helping stakeholders identify opportunities to outperform their competition. It also examines trade patterns, the industry value chain, recent news, and relevant policies and regulations. Additionally, the report provides customized solutions tailored to specific needs, and for any inquiries or customization requests, please feel free to contact us. 📍 By Regions and Countries ◘ North America (U.S., Canada, Mexico) ◘ Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe) ◘ Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC) ◘ South America (Brazil, Argentina, Rest of SA) ◘ Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA) ✅ Purchase This Research Report and Get 45% Discount with our limited-time offer! https://www.coherentmarketinsights.com/promo/buynow/2027 The report highlights key players and their competitive strategies, as well as emerging growth opportunities. It analyzes consumer behavior and preferences that influence market dynamics. The research incorporates quantitative methods to collect and analyze numerical data while also utilizing qualitative techniques-such as focus groups, observations, and interviews-to gain insights into subjective experiences and perspectives. All data and information are sourced from credible references to ensure an accurate and reliable market analysis, supporting the forecast of market size and growth potential for the period of 2024 to 2031. Additionally, the report examines regulatory factors and technological advancements that impact the market. Overall, this report serves as a valuable resource for those looking to make informed business decisions. 📌 Reasons to Purchase this Report: • Market Size Analysis: Analyze the Agricultural Biotechnology Market size by key regions, countries, product types, and applications. • Market Segmentation Analysis: Identify various subsegments within the Agricultural Biotechnology Market for effective categorization. • Key Player Focus: Focus on key players to define their market value, share, and competitive landscape. • SWOT Analysis: Conduct SWOT analyses of key players to assess their strengths, weaknesses, opportunities, and threats. • Development Plans: Review the development plans of key players for future strategic directions. • Growth Trends Analysis: Examine individual growth trends and future prospects in the Agricultural Biotechnology Market. • Market Contribution: Evaluate contributions of different segments to the overall Agricultural Biotechnology Market growth. • Growth Influencers: Detail key factors influencing market growth, including opportunities and drivers. • Industry Challenges: Discuss challenges and risks affecting the Agricultural Biotechnology Market. • Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market. ✅ Purchase This Premium Report Upto 45% Discount at: https://www.coherentmarketinsights.com/promo/buynow/2027 💬 Important Issues Resolved in the Report ◘ What is the projected market size and forecast for the years 2024 to 2031 for Agricultural Biotechnology Market? ◘ What opportunities and challenges exist for new entrants in the Agricultural Biotechnology market? ◘ What is the forecasted CAGR for the Agricultural Biotechnology market covering the years 2024 to 2031? ◘ What emerging trends are influencing the Agricultural Biotechnology market? ◘ Which region is estimated to hold the highest share of the market? ◘ What is the key factor driving the market? ◘ What are the main market segments, and how are they performing? ⏩ Author of this marketing PR: Priya Pandey is a dynamic and passionate PR writer with over three years of expertise in content writing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes writing contents and documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. ☎️ Contact Us: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Australia: +61-2-4786-0457 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com ⏩ About Us: Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. This release was published on openPR.

Fetterman on Oz confirmation vote: 'I never committed to a yes'House task force cites 'various failures' ahead of 'preventable' Trump shootingBOWLING GREEN, Ky. (AP) — Don McHenry scored 29 points as Western Kentucky beat Kentucky Wesleyan 91-71 on Saturday. McHenry also contributed four steals for the Hilltoppers (9-3). Braxton Bayless added 18 points while going 7 of 10 (3 for 3 from 3-point range) while they also had five rebounds. Julius Thedford went 6 of 13 from the field (3 for 7 from 3-point range) to finish with 17 points. It was the sixth straight win for the Hilltoppers. The Panthers were led in scoring by Quentin Toles, who finished with 15 points and six assists. Kentucky Wesleyan also got 14 points and six rebounds from Fatih Huyuk. Kennedy Miles also had 14 points and five assists. Western Kentucky took the lead with 5:32 remaining in the first half and did not relinquish it. The score was 46-41 at halftime, with Bayless racking up 13 points. Western Kentucky pulled away with an 8-0 run in the second half to extend a four-point lead to 12 points. They outscored Kentucky Wesleyan by 15 points in the final half, as McHenry led the way with a team-high 19 second-half points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

As her students finished their online exam, Arlet Lara got up to make a cafe con leche. Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. "I had a stroke, and my life made a 180-degree turn," Lara said, recalling the medical scare she experienced in May 2020 in the early months of the COVID-19 pandemic. "The stroke affected my left side of the body." Lara, an avid runner and gym-goer couldn't even walk. "It was hard," said the 50-year-old mom from North Miami and former high school math teacher. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved-nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. Every year, thousands in the United States have a stroke, with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System — the device implanted in Lara's chest — could be a game changer in recovery, said Dr. Robert Starke, a neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, where Lara underwent the procedure. How the device works The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara's occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body's nervous system. The electrical stimulation rewires the brain to improve a stroke survivor's ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. "Little by little, I'm noticing that my hand is getting stronger," Lara said in September. "I am already able to brush my teeth with the left hand." Since then, Lara has finished the initial six-week Vivistim therapy program and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Going beyond the 'plateau' Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors usually can recover some function through treatment and rehabilitation, they tend to hit a "major plateau" after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, "when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone." The device has even shown to benefit patients 20 years after their original stroke, according to Starke. "So now a lot of these patients that had strokes 10 to 15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous," Starke said. More about the device Vivistim's vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas' Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression. For Lara, the device is a new tool to help her recovery journey. "Everything becomes a challenge, so we are working with small things every day because I want to get back as many functions as possible," Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history. "Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue," the FDA said. MicroTransponder says the device is "covered by Medicare, Medicaid and private insurance with prior authorization on a case-by-case basis." Get local news delivered to your inbox!

LIMASSOL, Republic of Cyprus, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Eurasia Resource Value S.E. ("ERV”) today announced that it has acquired 1,052,632 common shares ("Common Shares”) of Condor Energies Inc. ("Condor”) (TSX: CDR) as part of a larger offering by Condor of Common Shares under the Listed Issuer Financing Exemption and other exemptions under National Instrument 45-106 Prospectus Exemptions of the Canadian Securities Administrators ("NI 45-106”), under which an aggregate of 10,198,582 Common Shares were issued (the "Offering”). ERV subscribed as an "accredited investor” under NI 45-106 and the aggregate consideration paid by ERV was CAD$2,000,000.80 or CAD$1.90 per share. Prior to the Offering, ERV held 13,399,905 Common Shares, or approximately 23.40% of the total issued and outstanding Common Shares. Following the Offering, ERV holds 14,452,537 Common Shares, or approximately 21.42% of the total issued and outstanding Common Shares. As Condor's largest shareholder before and after the Offering, ERV participated in the Offering for investment purposes as it believes the proceeds will position Condor to execute on its current business plan and strategy. An early warning report pursuant to National Instrument 62-103 The Early Warning System and Related Take-over Bid and Insider Reporting Issues will be filed on the Company's SEDAR+ profile at www.sedarplus.ca. A copy of the report may be obtained by contacting Norman Storm at ERV using the following contact information: EurAsia Resource Value S.E. ("ERV”) Griva Digeni 78, 1 st Floor, Office A1 3101 Limassol Republic of Cyprus [email protected] The Common Shares of Condor are traded on the Toronto Stock Exchange. Condor's head office address is: Condor Energies Inc. Suite 1810, 500 4 th Avenue SW Calgary, AB, T2P 2V6

Washington State wins 76-68 against Northern Iowa

STOCKTON, Calif. (AP) — Kolton Mitchell's 32 points led Idaho over Pacific 95-72 on Saturday night. Mitchell had six assists and three steals for the Vandals (5-8). Kristian Gonzalez added 20 points while shooting 7 for 11 (3 for 7 from 3-point range) and 3 of 3 from the free-throw line while they also had six rebounds. Julius Mims went 7 of 10 from the field to finish with 14 points, while adding nine rebounds and three blocks. Tyler Linhardt also had 14 points. Elias Ralph led the Tigers (5-9) in scoring, finishing with 18 points and seven rebounds. Lamar Washington added 14 points, six assists and two blocks for Pacific. Petar Krivokapic also had 13 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

Prosecutors have suggested to a New York judge the possibility of sparing Donald Trump any prison time for his conviction on charges involving hush money paid to a porn star in light of his US presidential election victory, but opposed dismissing the case. In a court filing made public on Tuesday, prosecutors with Manhattan District Attorney Alvin Bragg's office urged Justice Juan Merchan to deny the Republican businessman-turned-politicians' request to throw out the case so it does not hang over him and impede his ability to govern once he takes office on January 20. Noting that many of Trump's concerns involve the possibility that he could be incarcerated, prosecutors noted that there is no requirement that Merchan sentence him to prison - and said the judge could conclude that presidential immunity from prosecution would require a non-incarceration sentence. "Such a constitutional limitation on the range of available sentences would further diminish any impact on defendant's presidential decision-making without going so far as to discard the indictment and jury verdict altogether," prosecutors wrote. Merchan has not said when he will rule on Trump's bid for dismissal. Trump has called the case an attempt by Bragg, a Democrat, to harm his 2024 campaign. In a statement on Tuesday, Trump spokesperson Steven Cheung said, "Today's filing by the Manhattan DA is a pathetic attempt to salvage the remains of an unconstitutional and politically motivated hoax." The case stemmed from a $US130,000 ($A204,000) payment that Trump's former lawyer Michael Cohen made to adult film actress Stormy Daniels for her silence before the 2016 election about a sexual encounter she has said she had a decade earlier with Trump, who denies it. A Manhattan jury in May found Trump, 78, guilty of 34 counts of falsifying business records to cover up his reimbursement of Cohen. It was the first time a US president - former or sitting - had been convicted of or charged with a criminal offence. Falsifying business records is punishable by up to four years in prison, but incarceration is not required. Before his Nov. 5 election victory, legal experts told Reuters it was unlikely that Trump would be sentenced to prison due to his lack of a criminal history and advanced age, but that incarceration was not impossible. The US Supreme Court in July ruled in a separate criminal case involving Trump that presidents have broad immunity from criminal prosecution for official actions taken in office, and that evidence of official acts could not be used in prosecuting a president over personal acts. Trump's lawyers have argued that meant the case should be dismissed because prosecutors used statements that Trump made while president and testimony from his White House aides. The filing by Bragg's office on Tuesday said the hush money case involved "purely unofficial conduct."